Exceptional Revenue Growth
Revenue grew 33.9% YoY to $761.7M in Q1 FY2026 from $569.0M in Q1 FY2025, reflecting strong demand for PODD's insulin delivery products and continued market penetration.
INSULET CORP is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: PODD delivered a strong Q1 FY2026 with revenue surging 33.9% YoY to $761.7M and net income more than doubling to $91.1M, while the company returned $300M to shareholders via buybacks.
Drawn from management commentary in the Q1 2026 10-Q:
Revenue grew 33.9% YoY to $761.7M in Q1 FY2026 from $569.0M in Q1 FY2025, reflecting strong demand for PODD's insulin delivery products and continued market penetration.
Net income jumped 157.3% YoY to $91.1M from $35.4M, with EPS (diluted) rising to $1.30 from $0.50, indicating significant operating leverage as revenue growth outpaced expense growth.
R&D expenses increased 50.5% YoY to $89.7M, outpacing revenue growth, signaling continued heavy investment in product innovation and pipeline development to sustain long-term competitive positioning.
Revenue
$761.7M
++33.87% YoY
EPS (Basic)
$1.30
++160.00% YoY
Gross Margin
69.5%
-2.42% YoY
Operating Income
$122.1M
++37.50% YoY
Add PODD to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.